$0.67
4.50% yesterday
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.71
-0.25 26.17% 1M
-1.06 60.08% 6M
-0.03 4.32% YTD
-1.73 71.04% 1Y
-1.36 65.86% 3Y
-2.15 75.25% 5Y
-5.90 89.30% 10Y
Nasdaq, Closing price Wed, Feb 26 2025
+0.05 7.81%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Market capitalization $242.20m
Enterprise Value $89.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 17.15
P/S ratio (TTM) P/S ratio 46.31
P/B ratio (TTM) P/B ratio 1.36
Revenue growth (TTM) Revenue growth 884.75%
Revenue (TTM) Revenue $5.23m
EBIT (operating result TTM) EBIT $-211.12m
Free Cash Flow (TTM) Free Cash Flow $-208.39m
Cash position $258.37m
EPS (TTM) EPS $-0.75
P/E forward negative
P/S forward 21.76
EV/Sales forward 8.06
Short interest 26.40%
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5.23 5.23
887% 887%
100%
- Direct Costs 0.89 0.89
68% 68%
17%
4.34 4.34
43,300% 43,300%
83%
- Selling and Administrative Expenses 143 143
47% 47%
2,732%
- Research and Development Expense 72 72
25% 25%
1,377%
-211 -211
36% 36%
-4,026%
- Depreciation and Amortization 0.56 0.56
10% 10%
11%
EBIT (Operating Income) EBIT -211 -211
36% 36%
-4,037%
Net Profit -215 -215
36% 36%
-4,109%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
10 days ago
Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has publis...
Neutral
GlobeNewsWire
about one month ago
Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
Neutral
GlobeNewsWire
about 2 months ago
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025.
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 285
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today